Market Size in 2023 | Market Forecast in 2032 | CAGR (in %) | Base Year |
---|---|---|---|
USD 23.86 Billion | USD 33.67 Billion | 3.9% | 2023 |
According to the report published by Zion Market Research, the global Therapeutic Nuclear Medicines Market size was valued at USD 23.86 Billion in 2023 and is predicted to reach USD 33.67 Billion by the end of 2032. The market is expected to grow with a CAGR of 3.9% during the forecast period. The report analyzes the global Therapeutic Nuclear Medicines Market's growth drivers, restraints, and impact on demand during the forecast period. It will also help navigate and explore the arising opportunities in the Therapeutic Nuclear Medicines industry.
Therapeutic nuclear medicine is an effective drug detailing which consists of radioactive substances. These medicines are widely used for the therapy of metastasis bone tumors, cancer, and different infections. The radioactive substances are therapeutic nuclear medicines that are suitable for discarding the giant tissues along with lowering the size of the tumor and reducing treatment.
The growing acceptance of radiopharmaceuticals in therapeutic treatment purposes will drive the growth of the global therapeutic nuclear medicines market during the forecast period. The radiopharmaceuticals are increasingly being utilized in the diagnosis as well as the therapeutic treatment purposes. The prominent radiopharmaceutical companies are collaborating with cancer research institutes and big hospitals for the sale of their products, which in turn has led to the wide acceptance of nuclear medicines. The launch of advanced and efficient therapeutic nuclear medicines for the treatment of various kinds of cancers especially prostate cancer treatment will also spur market growth.
There are many therapeutic nuclear medicines launched in the market that have shown positive results in the treatment of prostate cancer, synovitis, and neuroblastoma. However, such achievements will significantly create lucrative opportunities in the global therapeutic nuclear medicines market during the forecast period. Moreover, nowadays therapeutic nuclear medicines are in demand even among the patient as well as the physicians. The growing prevalence of cancer all across the globe is another key factor driving the growth of the global therapeutic nuclear medicines market vigorously.
Also, nuclear medicines have seen a positive effect even in the treatment of thyroid and few other diseases in human beings. The ongoing research and development activities in the field of nuclear therapeutic medicines are likely to augment the growth of the global therapeutic nuclear medicines market during the forecast period. The growing initiatives from the government for the development of new techniques are likely to project the growth of the global market during the forecast period.
The global therapeutic nuclear medicines market can be segmented into the distribution channel, indication, treatment type, and region.
By distribution channel, the market can be segmented into cancer research institute, ambulatory surgical centers, and hospitals. The hospital segment accounts for the largest share in the global therapeutic nuclear medicines market due to the large pool of patients visiting hospitals for treatment.
By indication, the market can be segmented into the brain tumor, hepatic metastases, non-Hodgkin's lymphoma, synovitis, neuroblastoma, thyroid cancer, painful bone metastases, prostate cancers, and others. The prostate cancer segment holds the largest share in the global therapeutic nuclear medicines market. Thyroid cancer is anticipated to witness huge growth during the forecast period due to its increasing prevalence all across the globe.
By treatment, the market can be segmented into phosphorus 32, Arabian 169, rhenium 188 + rhenium 186, strontium 89, samarium-153, Yttrium-90, Lutetium-177, iodine 131, radium 223 and others.
Report Attributes | Report Details |
---|---|
Report Name | Therapeutic Nuclear Medicines Market |
Market Size in 2023 | USD 23.86 Billion |
Market Forecast in 2032 | USD 33.67 Billion |
Growth Rate | CAGR of 3.9% |
Number of Pages | 218 |
Key Companies Covered | International Isotopes Inc, Eckert & Ziegler, Lantheus Medical Imaging, Inc., ANSTO, Progenics Pharmaceuticals, Inc., Spectrum Pharmaceuticals, Curium Pharmaceuticals, Jubilant DraxImage, GE Healthcare, Bayer AG, and Novartis AG |
Segments Covered | By distribution channel, By indication, By treatment type and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
Base Year | 2023 |
Historical Year | 2018 to 2022 |
Forecast Year | 2024 - 2032 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
North America accounts for the largest share in the global therapeutic nuclear medicines market due to the growing investments from government authorities as well as prominent market players. Moreover, the growing research and development activities to develop advanced therapeutic nuclear medicines further boost the growth of the regional market.
Asia Pacific is anticipated to witness huge growth during the forecast period due to the growing initiatives from government authorities to strengthen the healthcare infrastructure in the region. Also, the growing adoption of therapeutic nuclear medications in the treatment of various diseases including thyroid and cancer is further propelling the growth of the regional market.
Some of the significant players in the global therapeutic nuclear medicines market are:
By indication
By treatment type
What Reports Provides
FrequentlyAsked Questions
The growing acceptance of radiopharmaceuticals in therapeutic treatment purposes is driving the growth of the global therapeutic nuclear medicines market during the forecast period. The radiopharmaceuticals are increasingly being utilized in the diagnosis as well as the therapeutic treatment purposes.
Some of the significant players in the global therapeutic nuclear medicines market are International Isotopes Inc, Eckert & Ziegler, Lantheus Medical Imaging, Inc., ANSTO, Progenics Pharmaceuticals, Inc., Spectrum Pharmaceuticals, Curium Pharmaceuticals, Jubilant DraxImage, GE Healthcare, Bayer AG, and Novartis AG.
North America accounts for the largest share in the global therapeutic nuclear medicines market due to the growing investments from government authorities as well as prominent market players. Moreover, the growing research and development activities to develop advanced therapeutic nuclear medicines further boost the growth of the regional market.
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed